Corium International, Inc. (CORI): David Greenwood , director of Corium International, Inc. purchased 3,000 shares on May 12, 2016. The Insider buying transaction was reported by the company on May 16, 2016 to the Securities and Exchange Commission. The shares were purchased at $3.58 per share for a total value of $10,742.40 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Feb 26, 2015, Peter D Staple (CEO) purchased 3,600 shares at $6.99 per share price.
Corium International Inc: On Friday, May 13, 2016 heightened volatility was witnessed in Corium International Inc which led to swings in the share price. The shares opened for trading at $3.2001 and hit $3.57 on the upside , eventually ending the session at $3.4, with a gain of 5.26% or 0.17 points. The heightened volatility saw the trading volume jump to 43,123 shares. The 52-week high of the share price is $16.2899 and the company has a market cap of $76 M . The 52-week low of the share price is at $3.14.
Company has been under the radar of several Street Analysts.Corium International Inc is Upgraded by WBB Securities to Speculative Buy and the brokerage firm has set the Price Target at $11. Earlier the firm had a rating of Hold on the company shares. The Rating was issued on May 3, 2016.
Corium International Inc. is a biopharmaceutical company. The Company is engaged in the development manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules or biologics including vaccines peptides and proteins as well as small molecules. Its Corplex and MicroCor platforms address the shortcomings of traditional transdermal drug delivery. Its marketed products include Clonidine TDS which is a treatment for hypertension; Fentanyl TDS which is a treatment for management of chronic pain and Crest Whitestrips are a series of five products for oral care. Its Twirla is designed to deliver both hormones at levels comparable to low-dose oral contraceptives. Its MicroCor hPTH(1?34) is a transdermal system designed to use its MicroCor technology to provide the delivery of parathyroid hormone.